All In Biotech

Drug Trial Radar · NCT06468202

Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Comparative Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 10,742 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

10,742

Planned (sponsor's estimate)

Start

Oct 18, 2024

Primary completion

Jan 1, 2029

Study completion Feb 1, 2030

Sponsor

Lead sponsor
Ohio State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Northwestern University; Preeclampsia Foundation
First posted
Jun 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 14 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.

Conditions

  • Hypertensive Disorders of Pregnancy
  • Preeclampsia
  • Gestational Hypertension

Interventions

  • Aspirin 81 mgDrug

    Participants will be assigned to 81mg Aspirin

  • Aspirin 162 mgDrug

    Participants will be assigned to 162mg Aspirin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hypertensive Disorder of Pregnancy (HDP)Time frame: From >20 weeks gestation until hospital discharge following delivery, up to 22 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Ochsner Baptist Medical Center

    New Orleans, Louisiana · Not yet recruiting

  • University of Mississippi

    Jackson, Mississippi · Active not recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • University of North Carolina, Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine

    Columbus, Ohio · Recruiting

  • University of Pittsburg Magee

    Pittsburgh, Pennsylvania · Recruiting

  • Brown University

    Providence, Rhode Island · Recruiting

  • University of South Carolina Greenville

    Greenville, South Carolina · Not yet recruiting

  • Austin Maternal Fetal Medicine

    Austin, Texas · Not yet recruiting

  • Baylor College of Medicine

    Houston, Texas · Not yet recruiting

  • University of Texas, Houston

    Houston, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Inova HealthSystem

    Falls Church, Virginia · Recruiting

  • Eastern Virginia Medical School - Old Dominion University

    Norfolk, Virginia · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.